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ABSTRACT
Introduction: Real-world data comparing 
outcomes of type 2 diabetes mellitus (T2DM) 
patients initiating different insulin regimens 
can help with treatment decisions and patient 
management. Clinical and economic outcomes 
following initiation with insulin glargine 
disposable pen (GLA-P) or insulin detemir 
disposable pen (DET-P) in T2DM patients were 
compared over 1-year follow-up. Methods: This 
retrospective cohort analysis was conducted 
on data in a US national managed care claims 
database (July 2006 to September 2010) from 
patients initiating insulin treatment with GLA-P 
or DET-P. Treatment persistence, adherence, 
glycated hemoglobin (A1C), hypoglycemic 
events, and healthcare costs during follow-up 
were compared. Results: In all, 1682 patients 
were identified; 1016 (60.4%) started using 
GLA-P, 666 (39.6%) started using DET-P. After 
1:1 propensity score matching, each cohort 
comprised 640 patients. Patients initiating 
GLA-P were significantly more likely to persist 
and adhere to treatment, and used a lower daily 
consumption dose. Over the last quarter of 
follow-up, fewer GLA-P users switched to DET-P 
compared with those switching from DET-P 
to GLA-P. GLA-P was associated with lower 
A1C levels and higher reduction of A1C levels 
from baseline, with no significant difference in 
the number of patients having hypoglycemic 
events. Patients in both cohorts had similar 
total and diabetes-related healthcare costs, but 
healthcare costs were lower in the GLA-P cohort 
for each 1% reduction in A1C from baseline. 
Conclusion: This real-world study demonstrates 
that patients initiating GLA-P were more likely 
to persist with and adhere to treatment, with 
better glycemic control and similar overall 
hypoglycemia rate at no increase in healthcare 
cost. 
Keywords: clinical outcomes, economic 
outcomes, insulin glargine, insulin detemir, type 
2 diabetes mellitus
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INTRODUCTION
The global prevalence of type 2 diabetes mellitus 
(T2DM) in 2010 was estimated to be 6.4% and 
this is expected to rise to 8% by 20301 due to 
an increasing aging population, increasing 
physical inactivity, prevalence of overweight 
people, and obesity.2,3 In the United States (US), 
diabetes affects an estimated 25.8 million people, 
equivalent to 8.3% of the US population,4 with 
T2DM comprising 90% to 95% of all diagnosed 
cases of diabetes.5 Untreated, T2DM can lead to 
several important clinical sequelae. Of particular 
significance is the established association between 
T2DM and an increased risk of cardiovascular 
complications, including coronary artery disease, 
peripheral artery disease, and carotid artery 
disease. In addition, microvascular complications 
leading to damage to the eyes, kidneys, or nerves, 
are also important in T2DM.6 As a chronic, 
progressively worsening disease, T2DM also 
carries an economic burden. In the USA, the total 
cost of diabetes was an estimated US$174 billion 
in 2007.5 This includes both direct medical costs 
(estimated at US$116 billion) and indirect costs 
(US$58 billion) incurred through treating the 
consequences of inadequate glycemic control 
and other complications of diabetes as well as 
costs associated with disability, work loss, and 
premature mortality.5,7,8
Tight (or intensive) glycemic control is 
beneficial in reducing the complications 
associated with diabetes6,9,10 and may, therefore, 
help reduce diabetes-related healthcare 
costs. Although oral medication is initially 
recommended for most patients with T2DM, 
insulin therapy is indicated once this is 
insufficient or if patients present with severe 
hyperglycemic signs or symptoms.11,12 Among 
adults with diagnosed diabetes, approximately 
27.9% used insulin therapy to manage 
and control their disease in 2008, either as 
monotherapy (15.5%) or in combination 
with oral medication (12.4%), whereas 48.5% 
used oral medicine only, and 23.6% were not 
using medication.13 The supplementation of 
oral glucose-lowering drugs with basal insulin 
analogs, such as insulin glargine and insulin 
detemir, can provide clinically important 
improvements in glycemic control with low 
risk of hypoglycemia.14 Although there are 
few comparative clinical trials, the two agents, 
insulin glargine and insulin detemir, have shown 
similar efficacy in terms of overall glycemic 
control, as well as similar tolerability profiles in 
terms of incidence of hypoglycemia.15-17 These 
results were also confirmed in one observational 
study that compared these insulin analogs in 
routine clinical practice. Insulin glargine and 
insulin detemir had improved efficacy results 
(glycemic control) compared with neutral 
protamine Hagedorn (NPH).18 It has been 
suggested that the similar degree of efficacy 
achieved with insulin glargine to insulin detemir 
can, however, be achieved with lower doses.19,20
Adequate control of T2DM helps to prevent 
the clinical sequelae and limit the financial 
consequences associated with the disease. In 
order to further characterize the healthcare 
outcomes associated with insulin glargine 
and insulin detemir in a real-world setting, an 
analysis of data from patients initiating insulin 
treatment with these agents was performed. It is 
important to note that this study was conducted 
with patients using disposable pen delivery 
devices for both therapies. Comparative studies 
have demonstrated that insulin pens have 
advantages over traditional vial and syringe 
injections in terms of patient preferences, 
discretion, ease of use, ease of reading the 
dose, improved accuracy for delivering small 
doses, and the ease of accurate dosing for older 
patients.21-24 Therefore, treatment comparisons 
using different delivery device mechanisms 
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may not reflect actual differences between 
therapies. The clinical outcomes and healthcare 
costs associated with use of the insulin glargine 
disposable pen (GLA-P: SoloSTAR®; Sanofi-
Aventis, Paris, France) and the insulin detemir 
disposable pen (DET-P: FlexPen®; Novo Nordisk, 
Bagsværd, Denmark) in patients using these 
devices for initiating T2DM therapy were 
compared.
Methods
This was a retrospective analysis of data from 
over 40 US healthcare plans collected in the 
Innovus IMPACT national managed care 
database between 2006 and 2010. This database 
contains information on medical claims, 
pharmacy claims, eligibility data, and laboratory 
results for 86.4 million patients, of whom 74% 
had pharmacy benefits and 15% had laboratory 
results.
Patient records were included in the analysis 
if they matched the following criteria: patients 
were diagnosed with T2DM, defined as having 
at least one inpatient visit or two physician 
visits dated at least 30 days apart with primary 
or secondary diagnosis of International 
Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) codes 250.x0 (T2DM 
or unspecified type not stated as uncontrolled) or 
250.x2 (T2DM or unspecified type uncontrolled); 
patients were on one or more oral antidiabetic 
drugs (OAD) or glucagon-like peptide-1 (GLP-1) 
medication; initiated insulin treatment using 
the GLA-P or DET-P device; aged 18-79 years 
old; and had continuous enrollment in a health 
plan for 6 months prior to the start of the 
GLA-P or DET-P use (the baseline period) and 
for 12 months after the initiation (the follow-up 
period). In addition, glycated hemoglobin (A1C) 
data were required at baseline and at the end of 
the 1-year follow-up for records to be included. 
Patient cohorts were determined by their use 
of either GLA-P or DET-P for insulin delivery at 
initiation.
Study Endpoints
A number of comparisons were made between 
the GLA-P and DET-P cohorts, including 
treatment persistence, defined as remaining 
on therapy without discontinuation during 
the 1-year follow-up from initiation. Study 
medication was considered discontinued if 
the prescription was not refilled within the 
expected time of medication coverage, defined 
as the 90th percentile of the time, stratified by 
the metric quantity supplied between first 
and second fills among patients with at least 
one refill. Sensitivity analyses of medication 
persistence were conducted using the 75th or 95th
percentiles of time-to-refill to define treatment 
discontinuation among patients with at least 
one refill and allow for longer-than-usual time 
between refills.
Also compared were: time-to-discontinuation, 
measured as days of being persistent with 
initiated therapy from the index date; treatment 
adherence, measured by both the traditional 
medication possession ratio (MPR), and the 
adjusted MPR taking into account the differences 
in insulin device package size during the 1-year 
follow-up, with the adjusted MPR calculated by 
multiplying the traditional MPR (the total days’ 
supply of all prescriptions in the analysis period 
as registered by the pharmacy when the insulin 
prescription is filled, divided by the number 
of days in the analysis period) by the average 
days between prescription refills for patients 
using insulin, divided by the average days’ 
supply for patients using insulin;25 daily average 
consumption (DACON), measured during the 
1-year follow-up period in units per day; glycemic 
control, measured by A1C level at the end of 
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1-year follow-up and the change from baseline 
A1C level; and hypoglycemic events, defined as 
a healthcare encounter (outpatient, inpatient 
or emergency department [ED] visit) with 
ICD-9-CM codes for the primary or secondary 
diagnosis for hypoglycemia during the 1-year 
follow-up period (250.8: diabetes with other 
specified manifestations; 251.0: hypoglycemic 
coma; 251.1: other specified hypoglycemia; and 
251.2: unspecified hypoglycemia).
Additionally, healthcare utilization, including 
the number of office visits, ED visits and 
endocrinologist visits, and the number and total 
duration of hospital admissions, were compared. 
Both total and diabetes-related healthcare 
costs were assessed from the perspective of US 
healthcare plan administrators during the 1-year 
follow-up. Costs were measured as standardized 
allowed payment (adjusted for inflation in 2009 
US$) by the health plan to the provider. Total 
cost was the sum of inpatient, outpatient, ED, 
and pharmacy prescription costs. Diabetes-
related cost included inpatient, outpatient, 
and ED care for T2DM, as well as diabetes 
medications and diabetes consumable items 
(needles, blood glucose test devices, etc).
Statistical Analysis
Comparing outcomes or deriving causal inference 
between patient cohorts in nonexperimental 
studies may have the possibility of overt bias, and 
results would be confounded by risk factors.26 
In order to overcome selection bias, propensity 
score matching at a matching ratio of 1:1 was 
applied to match patients in both cohorts, based 
on baseline demographic, comorbidity, A1C, 
OAD, and/or GLP-1 medication use, study drug 
copay, healthcare utilization, and cost data. 
All analyses were conducted on the 
matched cohorts. All study variables, including 
baseline and outcome measures, were analyzed 
descriptively. Percentages, means, SD, and 
P values were obtained and calculated using 
standard statistical tests and procedures. Time-




A total of 1682 eligible patient records were 
identified from the database. Of these, 1016 
patients (60.4%) initiated with GLA-P and 
666 patients (39.6%) initiated with DET-P. 
After propensity score matching, each cohort 
comprised 640 patients and there were no 
significant differences in demographic data, 
A1C, OAD, and/or GLP-1 medication use, 
comorbidities, hypoglycemia rates, healthcare 
utilizations, or healthcare costs between 
the GLA-P cohort and the DET-P cohort at 
baseline (multivariate analysis indicated P was 
nonsignificant for all baseline characteristics) 
(Table 1).
Treatment Persistence and Adherence
During the follow-up period, significantly more 
patients in the GLA-P cohort persisted with 
their treatment than those in the DET-P cohort
(64.8% vs. 50.9%, P<0.0001). In addition, 
the mean±SD number of days that patients 
persisted with their treatment was significantly 
higher in the GLA-P cohort than in the DET-P 
cohort (236.3±118.8 days vs. 212.8±114.9 days, 
respectively; P=0.0003). Kaplan-Meier analysis 
showed the GLA-P cohort were less likely to 
discontinue early than DET-P cohort (P<0.001) 
(Figure 1). 
Sensitivity analyses of medication persistence 
using the 75th percentiles of time-to-refill showed 
similar findings, with a higher persistence in 
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Table 1. Baseline characteristics of the matched insulin glargine disposable pen (GLA-P) and insulin detemir disposable pen 
(DET-P) cohorts (continued on next page).
  GLA-P (n=640) DET-P (n=640) P value
Demographics:
Men, n (%) 358 (55.9) 371 (58.0) 0.4630
Age, n (%):   
 18-39 years old 53 (8.3) 47 (7.3) 0.5320
 40-64 years old 507 (79.2) 517 (80.8) 0.4847
 65-74 years old 57 (8.9) 50 (7.8) 0.4796
 ≥75 years old 23 (3.6) 26 (4.1) 0.6621
 Mean±SD 55.00±10.1 54.81±10.2 0.7390
Health plan, n (%):   
 HMO 154 (24.1) 156 (24.4) 0.8962
 POS 337 (52.7) 323 (50.5) 0.4336
 PPO 100 (15.6) 94 (14.7) 0.6400
 Others 49 (7.7) 67 (10.5) 0.0797
Region, n (%):   
 North East 148 (23.1) 143 (22.3) 0.7388
 South 381 (59.5) 376 (58.8) 0.7762
 Midwest 42 (6.6) 48 (7.5) 0.5119
 West 68 (10.6) 72 (11.3) 0.7202
 Other 1 (0.2) 1 (0.2) 1.0000
Laboratory tests, mean±SD:
 A1C 9.4±2.0 9.4±2.0 0.8948
 Total cholesterol 176.3±77.8 173.7±59.8 0.5553
Comorbidities
Charlson Comorbidity Index, mean score±SD 0.58±1.2 0.64±1.3 0.3859
Comorbidities, n (%):   
 Hypertension 469 (73.3) 467 (73.0) 0.8997
 Hyperlipidemia 491 (76.7) 492 (76.9) 0.9472
 Myocardial infarction 13 (2.0) 17 (2.7) 0.4599
 Congestive heart failure 32 (5.0) 31 (4.8) 0.8972
 Peripheral vascular disease  24 (3.8) 33 (5.2) 0.2226
 Renal disease 37 (5.8) 35 (5.5) 0.8083
 Retinopathy 53 (8.3) 67 (10.5) 0.1794
 Neuropathy 74 (11.6) 66 (10.3) 0.4737
 Nephropathy 30 (4.7) 39 (6.1) 0.2653
 Chronic pulmonary disease 57 (8.9) 62 (9.7) 0.6303
 Cancer 34 (5.3) 39 (6.1) 0.5467
 Mental illness 80 (12.5) 86 (13.4) 0.6177
 Severe mental illness 23 (3.6) 22 (3.4) 0.8794
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the GLA-P cohort (at 75th percentiles: 41.0% vs. 
31.2%; P=0.0002; at 95th percentiles: 74.3% vs. 
61.2%; P<0.0001). 
At the end of the 1-year follow-up, fewer 
patients in the GLA-P cohort switched to
DET-P compared with patients in the DET-P
cohort who switched to GLA-P (1.4% vs. 5.9%; 
P<0.0001). 
Patient adherence to treatment was also 
significantly higher in the GLA-P cohort 
Table 1. (Continued) Baseline characteristics of the matched insulin glargine disposable pen (GLA-P) and insulin detemir 
disposable pen (DET-P) cohorts.
  GLA-P (n=640) DET-P (n=640) P value
Oral antidiabetic medication, n (%):
 Metformin 532 (83.1) 526 (82.2) 0.6578
 Sulfonylureas 440 (68.8) 442 (69.1) 0.9039
 DPP4 190 (29.7) 177 (27.7) 0.4217
 GLP-1 135 (21.1) 126 (19.7) 0.5324
 Thiazolidinediones 242 (37.8) 262 (40.9) 0.2526
 Meglitinides 37 (5.8) 36 (5.6) 0.9041
 Alpha-glucosidase 8 (1.3) 8 (1.3) 1.0000
Any hypoglycemia at baseline, n (%) 18 (2.8) 16 (2.5) 0.7281
Healthcare utilization, n (%):
 Any hospitalization 48 (7.5) 67 (10.5) 0.0633
 Any ED visit 113 (17.7) 130 (20.3) 0.2257
 Any office visit 637 (99.5) 635 (99.2) 0.4781
 Any endocrinologist visit 205 (32.0) 204 (31.9) 0.9522
Diabetes-related healthcare utilization, n (%):
 Any diabetes-related hospitalization 37 (5.8) 46 (7.2) 0.3070
 Any diabetes-related ED visit 42 (6.6) 47 (7.3) 0.5827
 Any diabetes-related office visit 625 (97.7) 625 (97.7) 1.0000
Total cost (US$), mean±SD:
 Total cost 6736±11,343 7915±13,702 0.0938
 Inpatient cost 1849±8836 2486±10,160 0.2311
 Outpatient cost 2522±4335 2946±6116 0.1519
 ED cost 220±750 260±827 0.3667
 Treatment cost 2146±2022 2222±2210 0.5169
Total diabetes-related cost (US$), mean±SD:
 Diabetes-related total cost 2671±4706 3246±7412 0.0975
 Diabetes-related inpatient cost 827±4101 1221±5498 0.1467
 Diabetes-related outpatient cost 818±1357 1010±3495 0.1956
 Diabetes-related ED cost 119±539 110±519 0.7398
 Diabetes-related treatment cost 832±716 829±717 0.9482
 Diabetes supply cost 75±137 77±128 0.7527
A1C=glycated hemoglobin; DPP4=dipeptidyl peptidase-4; ED=emergency department; GLP-1=glucagon-like peptide-1; 
HMO=Health Maintenance Organization; POS=point-of-service plan; PPO=preferred provider organization. 
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compared with the DET-P cohort (MPR: 
0.48±0.26 vs. 0.44±0.28; P=0.0049; adjusted 
MPR: 0.70±0.30 vs. 0.63±0.33; P<0.0001). In 
addition, among patients in the GLA-P cohort, 
significantly more had an adjusted MPR ≥0.8 




At the end of the 1-year follow-up, patients who 
initiated with GLA-P had significantly lower A1C 
levels as well as significantly greater reductions 
in A1C levels from baseline. Mean A1C for the 
GLA-P users at the end of the 1-year follow-up 
was 8.1±1.6% compared with 8.4±1.8% for the 
DET-P users (P=0.0260) (Figure 2). Patients in 
the GLA-P cohort had a mean change in A1C 
from baseline levels of −1.23 (95% CI, −1.39%, 
−1.06%) whereas patients in the DET-P cohort 
had a change from baseline of −1.00 (95% CI, 
−1.16%, −0.84%; P=0.0467) (Figure 2). There was 
no significant difference in the proportion of 
patients achieving A1C<7.0% (23.9% vs. 23.3%; 
P=0.79)
DACON
The DACON dose of insulin was significantly 
lower in the GLA-P cohort than in the DET-P 
cohort (29.0±19.1 units/days vs. 31.8±23.3
units/days, respectively; P=0.03). Due to the 
higher A1C reduction in the GLA-P cohort (−1.23%
vs. −1.00%), population-wise, for each 1% 
reduction in A1C the mean required DACON 
dose was 23.6 units/days in the GLA-P cohort 
compared with 31.8 units/days in the DET-P 
cohort.
During the follow-up period, rapid-acting 
insulin was used by 118 patients (18.4%) in 
the GLA-P cohort and 117 patients (18.3%) in 
the DET-P cohort. The mean DACON dose of 
rapid-acting insulin was lower in the patients 
in the GLA-P cohort compared with patients in 
the DET-P cohort; this difference did not reach 
statistical significance (35.2±28.7 units/days vs. 
40.4±33.9 units/days; P=0.2074).
Hypoglycemia
The proportion of patients who incurred a 
hypoglycemic event during the 1-year follow-up 
was low and similar in both patient cohorts 
(7.9% in the GLA-P cohort and 5.9% in the 
DET-P cohort; P=0.1531), as was the mean 
number of hypoglycemic events per patient 
per year (0.23±1.26 vs. 0.13±0.87; P=0.09). The 
mean number of hypoglycemia-related ED visits 
or hospitalizations per patient per year was 
low, but was statistically significantly higher 
in the GLA-P cohort compared with the DET-P 
cohort (0.04±0.24 vs. 0.02±0.13, respectively; 
P=0.0455).
Overall, both a higher DACON dose and 
a higher number of hypoglycemic events 
during the 1-year follow-up were significantly 
correlated with a higher reduction in A1C 
(correlation coefficient: −0.091; P=0.0012, 
and correlation coefficient: −0.098; P=0.0012, 
respectively).
Figure 1. Kaplan-Meier curve for time-to-discontinuation 
of initiated insulin therapy among the matched insulin 
glargine disposable pen (GLA-P) and insulin detemir 
disposable pen (DET-P) cohorts. Medication persistence 
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Economic Outcomes
There were no significant differences in 
healthcare utilization outcomes between the 
GLA-P cohort and the DET-P cohort for the 
percentage of patients with hospitalization (all-
cause healthcare utilization 13.9% vs. 12.5%; 
diabetes-related healthcare utilization: 10.2% 
vs. 8.0%, for GLA-P and DET-P, respectively),
the percentage of patients with any office visits 
(all cause: 100% vs. 99.8%; diabetes related: 
99.4% vs. 99.7%), or for the percentage of 
patients with ED visits (all cause: 28.3% vs. 
24.2%; diabetes related: 10.2% vs. 7.8%). The 
mean number of office visits per patient over 
the 1-year follow up was similar for GLA-P and 
DET-P users (all cause: 18.9 vs. 17.9; diabetes 
related: 7.7 vs. 7.9), as was the number of 
endocrinologist visits (3.1 vs. 2.8). The mean 
number of hospitalizations or ED visits per 
patient, whether all cause or diabetes related, 
was below 0.8 in either cohort. Patients also 
had similar total and diabetes-related healthcare 
costs across both cohorts (Figure 3). Study 























































Figure 2. Glycated hemoglobin (A1C) reduction from baseline (left) and A1C levels (right) after 1-year follow-up 
associated with insulin glargine disposable pen (GLA-P) compared with insulin detemir disposable pen (DET-P) treatment. 
*Error bars are 95% confidence intervals.
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However, due to the higher A1C reduction 
in the GLA-P cohort (−1.23% vs. −1.00%), 
population-wise, for each 1% reduction in A1C 
the total and diabetes-related healthcare costs 
were US$13,059 and US$5732 in the GLA-P 
cohort compared with US$15,350 and US$6287 
in the DET-P cohort.
DISCUSSION
The results from this real-world study showed 
that, after 1-year follow-up, patients with 
T2DM initiating insulin treatment with GLA-P 
were more likely to persist with and adhere to 
treatment compared with patients initiating 
with DET-P. In addition, patients initiating 
with GLA-P had better A1C reduction at the 
end of follow-up, associated with a lower daily 
average consumption of insulin, and similar 
overall hypoglycemia rates, without additional 
healthcare costs or healthcare resource 
utilization during the 1-year follow-up period. 
Therefore, the insulin dose required and the 
costs needed to achieve a 1% A1C reduction 
were lower with GLA-P than with DET-P. 
The results of this study are important 
because they provide a comprehensive real-
world comparison of the two basal insulin 
analogs (including both clinical and economic 
outcomes) using delivery devices with similar 
mechanisms, and can help optimize the 
management of patients with T2DM. Individual 
randomized clinical trials have reported similar 
efficacy and rates of hypoglycemia of insulin 
glargine and insulin detemir in insulin-naive 
patients.14,16,19,27 A recently published Cochrane 
review confirmed these findings but also showed 
significant heterogeneity across studies.30 
Prespecified sensitivity analysis was used to 
address this issue and found that the mean 
difference in endpoint A1C levels between the 
two insulin analogs was statistically significant 
Figure 3. The 1-year outcomes of overall (all-cause) and diabetes-related healthcare costs associated with insulin glargine 
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in favor of insulin glargine (mean difference: 
0.16%; 95% CI, 0.01, 0.32%). Our study 
reported a larger difference at 0.23%; this may 
relate to differences between controlled and 
real-world settings, such as patients’ persistence 
or compliance with therapies. 
With respect to economic and healthcare 
utilization, the results from this study showed 
that, although the costs associated with 
either treatment are comparable, GLA-P may 
be a more cost-effective option than DET-P 
as measured by the cost to achieve an A1C 
reduction of 1%. These results are suggestive 
because there has been limited published 
data in the literature and the current study’s 
design was not necessarily compatible with 
the study design of published work. A German 
study found that the annual treatment costs 
associated with insulin glargine were 36% lower 
compared with those with insulin detemir.28 In 
a Canadian study, the cost savings associated 
with lifetime insulin glargine use were CA$4659 
per patient compared with once-daily insulin 
detemir, and CA$8709 per patient compared 
with twice-daily insulin detemir.29
The limitations of this study include that 
the population being examined was from a 
managed care setting, and is therefore not 
representative of the US population as a whole. 
Claims data submitted by healthcare providers 
to insurance companies are subject to possible 
coding errors. Data on weight is not available, 
and weight gain during therapy is a concern for 
patients and a possible event associated with 
treatment. With regards to the pharmacy claim 
data used in this study, they may not accurately 
reflect daily insulin dose as patients may discard 
unused insulin portions at the in-use expiration 
date or skip doses, and this might artificially 
inflate or deflate the dose results, and also may 
affect the accuracy of persistence measurement. 
Dosing information (eg, once-daily dose or 
twice-daily dose) was not available in this 
database. 
A review of data from randomized 
controlled trials suggested that 13.6% to 57.2% 
of patients on insulin detemir were injecting 
twice daily at the end of the trial, whereas 
insulin glargine was mostly injected once 
daily. In addition, the proportion of patients 
with injection-site reactions was significantly 
lower with insulin glargine than with insulin 
detemir.30 This could have an implication on 
patient compliance with insulin treatment 
in the routine practice, and possibly explain 
the difference in persistence and adherence 
observed in the current study. 
Diabetes duration was not available 
in the dataset and would improve the 
matching. However, the authors believe that 
many variables, such as the number of oral 
antidiabetes medications and A1C that were 
controlled for in the propensity score matching, 
were also correlated with diabetes duration. 
Therefore, the diabetes duration was controlled 
indirectly. Finally, as with any retrospective 
studies, the findings from the current study are 
only hypothesis generating, and no causality 
can be established until randomized pragmatic 
clinical trials are conducted to confirm these 
hypotheses. Although propensity score 
matching can control for the observed bias, 
hidden bias might still be available due to the 
unavailable variables, such as disease severity. 
To the extent that severity is more correlated 
with one group, relative to the other, our 
results will be biased. Pearl suggests that hidden 
bias actually increases because matching bias 
on observed variables may unleash bias due 
to dormant observed confounders.31 There are 
other statistical techniques available to control 
for the hidden bias, such as instrumental 
variable approach. However, these methods are 
also bounded with their own limitations.32
1010 Adv Ther (2011)  28(11):1000-1011.
CONCLUSION
The current study in real-world T2DM patients 
initiating insulin treatment via disposable pen 
suggests that, comparing with insulin detemir, 
the use of insulin glargine may be associated 
with better persistence and compliance with 
treatment, and higher A1C reduction with 
a similar overall rate of hypoglycemia, at no 
increased cost, and, therefore, may be a more 
cost-effective treatment option. These data may 
assist the clinical decision-making process in 
routine practice settings for the treatment of 
patients with T2DM and help optimize patient 
management. However, these findings need to 
be confirmed with future randomized pragmatic 
clinical trials.
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